FunPep Company Limited [4881.T]
TOKYO, Mar 31 (Pulse News Wire) – FunPep Company Limited (4881.T) detailed its strategy to enhance its antibody-inducing peptide technology, focusing on the development of treatments for skin ulcers and allergies. The company's lead product, SR379, is undergoing additional Phase III clinical trials aimed at expanding its application in treating various types of skin ulcers, including diabetic foot ulcers.
Additionally, FunPep reported positive interim results from the Phase I/IIa clinical trial of its allergy vaccine candidate, FPP004X, which showed significant antibody responses in high-dose cohorts. The study also confirmed sustained antibody levels without notable adverse effects.
Looking ahead, FunPep plans to invest approximately ¥200 million in securing exclusive rights for global research, development, and commercialization of FPP004X, contingent upon successful option exercise. The company expects this investment to drive future revenue streams and strengthen its position in the pharmaceutical sector.
🟡 Confidence: Standard AI-translated content.